FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

• Published in: Clinical cancer research Vol. 27; no. 7; pp. 1850 - 1854
• Main Authors: Wahby, Sakar, Fashoyin-Aje, Lola, Osgood, Christy L, Cheng, Joyce, Fiero, Mallorie H, Zhang, Lijun, Tang, Shenghui, Hamed, Salaheldin S, Song, Pengfei, Charlab, Rosane, Dorff, Sarah E, Ricks, Tiffany K, Barnett-Ringgold, Kimberly, Dinin, Jeannette, Goldberg, Kirsten B, Theoret, Marc R, Pazdur, Richard, Amiri-Kordestani, Laleh, Beaver, Julia A
• Format: Journal Article
• Language: English
• Published: United States 01-04-2021
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Camptothecin - pharmacology; Camptothecin - therapeutic use; Drug and Narcotic Control; Drug Approval; Female; Humans; Immunoconjugates - adverse effects; Immunoconjugates - pharmacology; Immunoconjugates - therapeutic use; Middle Aged; Neoplasm Metastasis; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - pathology
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.ccr-20-3119

On April 22, 2020, the FDA granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY; Immunomedics, Inc.) for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Approval was based on data from the IMMU-132-01 trial, a single-arm, multicohort, multicenter, phase I/II trial of sacituzumab govitecan. The assessment of efficacy was based on 108 patients with mTNBC who had previously received at least two prior lines of therapy in the metastatic setting and who received sacituzumab govitecan 10 mg/kg i.v. The assessment of safety was based on 408 patients with advanced solid tumors who had received sacituzumab govitecan at doses up to 10 mg/kg i.v. The primary efficacy endpoint was investigator-assessed objective response rate (ORR) and duration of response (DoR) was a key secondary endpoint. The ORR was 33.3% [36/108; 95% confidence interval (CI), 24.6-43.1], and median DoR among responders was 7.7 months (95% CI, 4.9-10.8). The most common adverse reactions occurring in ≥25% of patients were nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, and abdominal pain. This article summarizes the FDA review process and data supporting the approval of sacituzumab govitecan.